NASDAQ: INDV
Indivior PLC Stock

$15.41+0.01 (+0.06%)
Updated Jul 3, 2025
INDV Price
$15.41
Fair Value Price
N/A
Market Cap
$1.92B
52 Week Low
$7.33
52 Week High
$15.58
P/E
256.83x
P/B
-6.75x
P/S
1.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.17B
Earnings
$3.00M
Gross Margin
80.4%
Operating Margin
4.53%
Profit Margin
0.3%
Debt to Equity
-5.83
Operating Cash Flow
$136M
Beta
0.93
Next Earnings
Jul 24, 2025
Ex-Dividend
N/A
Next Dividend
N/A

INDV Overview

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine INDV's potential to beat the market

AStrong Buy
  • Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
INDV
Ranked
#4 of 62

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important INDV news, forecast changes, insider trades & much more!

INDV News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INDV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

INDV is poor value based on its earnings relative to its share price (256.83x), compared to the US market average (30.96x)
P/E vs Market Valuation
INDV is good value based on its earnings relative to its share price (256.83x), compared to the US Drug Manufacturers - Specialty & Generic industry average (-75.55x)
P/E vs Industry Valuation
INDV's Earnings (EBIT) of $53.00M... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more INDV due diligence checks available for Premium users.

Valuation

INDV price to earnings (PE)

For valuing profitable companies with steady earnings

Company
256.83x
Industry
-75.55x
Market
30.96x
INDV is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INDV is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

INDV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-6.75x
Industry
2.28x

INDV's financial health

Profit margin

Revenue
$266.0M
Net Income
$47.0M
Profit Margin
17.7%
INDV's Earnings (EBIT) of $53.00M... subscribe to Premium to read more.
Interest Coverage Financials
INDV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.4B
Liabilities
$1.7B
Debt to equity
-5.83
INDV's short-term liabilities ($1.01B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INDV's short-term assets ($883.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INDV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INDV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$75.0M
Investing
-$5.0M
Financing
-$17.0M
INDV's operating cash flow ($136.00M)... subscribe to Premium to read more.
Debt Coverage Financials

INDV vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
INDVA$1.92B+0.06%256.83x-6.75x
SUPNC$1.79B-0.28%28.30x1.74x
EVOC$1.49B-3.23%N/A1.44x
ANIPB$1.41B+0.09%-51.81x3.38x
BHCC$2.61B-0.84%-64.18x-2.21x

Indivior Stock FAQ

What is Indivior's quote symbol?

(NASDAQ: INDV) Indivior trades on the NASDAQ under the ticker symbol INDV. Indivior stock quotes can also be displayed as NASDAQ: INDV.

If you're new to stock investing, here's how to buy Indivior stock.

What is the 52 week high and low for Indivior (NASDAQ: INDV)?

(NASDAQ: INDV) Indivior's 52-week high was $15.58, and its 52-week low was $7.33. It is currently -1.09% from its 52-week high and 110.23% from its 52-week low.

How much is Indivior stock worth today?

(NASDAQ: INDV) Indivior currently has 124,769,533 outstanding shares. With Indivior stock trading at $15.41 per share, the total value of Indivior stock (market capitalization) is $1.92B.

Indivior stock was originally listed at a price of $22.77 in Jun 12, 2023. If you had invested in Indivior stock at $22.77, your return over the last 2 years would have been -32.32%, for an annualized return of -17.73% (not including any dividends or dividend reinvestments).

How much is Indivior's stock price per share?

(NASDAQ: INDV) Indivior stock price per share is $15.41 today (as of Jul 3, 2025).

What is Indivior's Market Cap?

(NASDAQ: INDV) Indivior's market cap is $1.92B, as of Jul 5, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Indivior's market cap is calculated by multiplying INDV's current stock price of $15.41 by INDV's total outstanding shares of 124,769,533.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.